Abstract Both machine learning and physiologically-based pharmacokinetic models are becoming essential components of the drug development process. Integrating the predictive capabilities of physiologically-based pharmacokinetic (PBPK) models within machine learning (ML) pipelines could offer significant benefits in improving the accuracy and scope of drug screening and evaluation procedures. Here, we describe the development and testing of a self-contained machine learning module capable of faithfully recapitulating summary pharmacokinetic (PK) parameters produced by a full PBPK model, given a set of input drug-specific and regimen-specific information. Because of its widespread use in characterizing the disposition of orally administered d...
The ability to predict human pharmacokinetics in early stages of drug development is of paramount im...
Approximately 40%-60% of developing drugs failed during the clinical trials because of ADME/Tox defi...
During drug discovery and prior to the first human dose of a novel candidate drug, the pharmacokinet...
Abstract The gold‐standard approach for modeling pharmacokinetic mediated drug–drug interactions is ...
Pharmacometrics (PM) and machine learning (ML) are both valuable for drug development to characteriz...
Pharmacometrics (PM) and machine learning (ML) are both valuable for drug development to characteriz...
Although computational predictions of pharmacokinetics (PK) are desirable at the drug design stage, ...
© 2022 by the authors.Pharmacometrics is a multidisciplinary field utilizing mathematical models of ...
Physiologically based pharmacokinetic (PBPK) models are employed broadly throughout the pharmaceutic...
Oral bioavailability (F) is an essential determinant for the systemic exposure and dosing regimens o...
Abstract Many machine learning techniques provide a simple prediction for drug-drug interactions (DD...
AbstractPhysiologically based pharmacokinetic (PBPK) modeling and simulation can be used to predict ...
Allometric scaling is widely used to predict human pharmacokinetic parameters from preclinical speci...
Physiologically Based Pharmacokinetic (PBPK) models are mechanistic tools generally employed in the ...
Physiologically Based Pharmacokinetic (PBPK) models are mechanistic tools generally employed in the ...
The ability to predict human pharmacokinetics in early stages of drug development is of paramount im...
Approximately 40%-60% of developing drugs failed during the clinical trials because of ADME/Tox defi...
During drug discovery and prior to the first human dose of a novel candidate drug, the pharmacokinet...
Abstract The gold‐standard approach for modeling pharmacokinetic mediated drug–drug interactions is ...
Pharmacometrics (PM) and machine learning (ML) are both valuable for drug development to characteriz...
Pharmacometrics (PM) and machine learning (ML) are both valuable for drug development to characteriz...
Although computational predictions of pharmacokinetics (PK) are desirable at the drug design stage, ...
© 2022 by the authors.Pharmacometrics is a multidisciplinary field utilizing mathematical models of ...
Physiologically based pharmacokinetic (PBPK) models are employed broadly throughout the pharmaceutic...
Oral bioavailability (F) is an essential determinant for the systemic exposure and dosing regimens o...
Abstract Many machine learning techniques provide a simple prediction for drug-drug interactions (DD...
AbstractPhysiologically based pharmacokinetic (PBPK) modeling and simulation can be used to predict ...
Allometric scaling is widely used to predict human pharmacokinetic parameters from preclinical speci...
Physiologically Based Pharmacokinetic (PBPK) models are mechanistic tools generally employed in the ...
Physiologically Based Pharmacokinetic (PBPK) models are mechanistic tools generally employed in the ...
The ability to predict human pharmacokinetics in early stages of drug development is of paramount im...
Approximately 40%-60% of developing drugs failed during the clinical trials because of ADME/Tox defi...
During drug discovery and prior to the first human dose of a novel candidate drug, the pharmacokinet...